Oral Minoxidil vs Spironolactone: Head-to-Head Efficacy Compared

Compare the Treatment Goal First

Acne and hair thinning can occur together, but they are separate outcomes. Fewer acne lesions, a change in scalp hair count, and a patient's report of less shedding are not interchangeable measures of efficacy.

Oral minoxidil is a vasodilator, and its use for hair loss differs from its labeled hypertension indication. Spironolactone is an aldosterone antagonist with antiandrogen effects relevant to dermatology. The different mechanisms explain why clinicians may consider different treatment targets, but mechanisms alone do not prove comparative effectiveness. [1,2]

Hair-Loss Evidence: Keep the Designs Separate

Randolph and Tosti's review, published in 2021, identified 17 oral-minoxidil studies with 634 patients through April 2020. Androgenetic alopecia was the most studied diagnosis; other conditions appeared in smaller bodies of evidence. The authors called for larger randomized studies with standardized measurements. A review spanning several diagnoses does not prove equal effectiveness for every type of hair loss. [5]

The 2005 antiandrogen study included 80 women, not 395. Forty received spironolactone and 40 received cyproterone acetate. Across the combined groups after at least 12 months, 44% had regrowth, 44% had no clear change and 12% continued losing hair. This was an open before-and-after study without a placebo group. Serum hormone levels were not a significant predictor of response in its analysis. Those pooled findings cannot be presented as a spironolactone-only response rate or proof that raised androgens identify the best responders. [6]

For the treatment-specific evidence, see oral-minoxidil results. A percentage from a safety cohort should not replace an actual measure of hair growth.

Combination Therapy: What Is Established and What Is Still Uncertain

Sinclair's 2018 study followed 100 women taking oral minoxidil 0.25 mg and spironolactone 25 mg daily. Hair-loss severity and shedding scores improved at six and twelve months. Every participant received both medicines, and the study was uncontrolled. It cannot separate each drug's contribution or establish that the combination works better than either alone. Its fixed study regimen is not evidence for a universal three-month titration protocol. [4]

A 2025 randomized pilot provides a different comparison. Forty-eight premenopausal women received spironolactone 100 mg or placebo for 24 weeks, while everyone used topical minoxidil 3%. Moderate-to-marked photographic improvement favored spironolactone, 38% versus 9%. The terminal-hair-count comparison did not reach conventional statistical significance, with P=.063. The sample was small, and the background minoxidil was topical. This result should not be converted into a trial of oral minoxidil versus spironolactone. [7]

A separate 54-patient retrospective study examined unwanted hair growth, not a randomized comparison of scalp-hair efficacy. The combination group had a lower observed hypertrichosis rate, but the difference was not statistically significant. It does not prove that adding spironolactone prevents oral-minoxidil hypertrichosis. [10]

Acne: Read SAFA's Endpoint and Time Point Correctly

SAFA randomized 410 adult women with persistent facial acne to spironolactone or placebo, with topical treatments allowed. Its study regimen increased from 50 mg to 100 mg at week six. The primary outcome was an acne quality-of-life symptom score at week twelve. [3]

Investigator-assessed treatment success was 19% versus 6% at twelve weeks, not twenty-four. At twenty-four weeks, participant-reported improvement was 82% versus 63%. These are different measures; neither means that everyone achieved clear skin. The treatment differences generally grew by twenty-four weeks. Oral minoxidil was not a comparator. [3]

The earlier 2017 spironolactone review found low or very low quality evidence in its included trials. SAFA adds a more substantial placebo-controlled trial for adult female acne, without answering every hair-loss question. [11]

Side Effects: Compare Actual Cohorts

The 1,404-patient oral-minoxidil safety study was retrospective, included several alopecia diagnoses and had no control group. Hypertrichosis occurred in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%. It did not report the claimed 62% good-or-excellent hair-growth response. Its overall rates are not a validated prediction for a particular 5 mg regimen. [8]

Spironolactone can cause menstrual or breast changes, and potassium and kidney context matter. In the 2025 hair-loss pilot, menstrual irregularities occurred in 37.5% of the spironolactone group. That trial-specific observation differs from a general estimate for all dermatology patients. [2,7]

The 2015 potassium study involved 974 healthy young women and excluded cardiovascular disease, renal failure and medicines affecting the renin-angiotensin-aldosterone system. Its 0.72% figure described abnormal potassium measurements, not a guarantee for patients outside that selected population. [9]

Dosing, Switching and Monitoring

The doses above identify research regimens. They do not provide a personal dose recommendation, a standardized taper, or evidence that switching is automatically safe because the medicines have different mechanisms. Both medicines can affect blood pressure, and adding, replacing or stopping treatment changes the clinical question.

The international oral-minoxidil Delphi consensus covers baseline evaluation, monitoring, precautions and consultation. It is expert consensus, and its titration items did not reach consensus. It does not establish a universal ECG-at-2.5-mg rule or one monitoring calendar for every patient. [12]

For spironolactone, the current Aldactone label calls for potassium assessment within a week of starting or changing treatment and regular assessment afterward. Selected low-risk acne cohorts and a product label address different populations; the study's exclusions matter when the prescriber sets the actual monitoring plan. [2,9]

The current spironolactone label advises avoiding use during pregnancy because of its potential antiandrogen effect on male fetal development. Pregnancy planning remains relevant to a treatment decision. [2]

Set an Outcome and a Review Period

For acne, track the acne outcome. For hair loss, track hair density, shedding or photographic change consistently enough to compare over time. Study follow-up at six, twelve or twenty-four months does not guarantee the same response date for an individual.

The sources here do not establish a universal oral-minoxidil withdrawal interval of three to six months or a taper that prevents loss of treatment benefit. A change in treatment should be assessed against the original diagnosis and the treatment goal, rather than assuming one medicine replaces every benefit of the other.

Cost also depends on tablet strength, formulation, pharmacy, quantity and coverage. Off-label dermatology use does not establish either an automatic insurance approval or an automatic exclusion. A specific current quote is more useful than an unsupported price range.